Industry News

Masimo announced today that in response to the Zika virus and its potential impact on the availability of blood products, Masimo is creating a special program to dramatically reduce the cost of and increase access to Masimo’ s continuous hemoglobin monitoring solutions, shown to help clinicians reduce blood transfusions in both low and high blood loss surgery. This special program will be available wherever the blood supply is affected by the Zika virus."/>
Masimo Announces a Special Worldwide Program for Total Hemoglobin (SpHb®) Monitoring for Areas Affected by the Zika Virus
Medovex Corp., a developer of medical technology products, today announced that the Company has hired Mr. Juan Davila as Director Sales& Marketing for their DenerveX™ division of the business. Davila, a Sales& Marketing leader with more than over 20 years of experience in the Latin-American Market, is recognized for his excellent record of business growth and market development of new products in the highly competitive medical devices industry in Latin..."/>
Medovex Corporation Expands Launch Plan With Latin American Management Hire
Heron Therapeutics, Inc., a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced that preliminary, positive, top-line results from Heron’ s Phase 2 study of HTX-011 in patients undergoing inguinal hernia repair will be presented in two posters at PAINWeek ®, the national conference on pain for frontline practitioners, on Thursday, September 8,..."/>
Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016
Intersect ENT, Inc., a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that CareFirst BlueCross BlueShield, the regional blues provider for Maryland and the National Capital area, has issued a positive coverage decision for PROPEL ® and PROPEL ® mini steroid..."/>
Intersect ENT Announces Positive Coverage Decision by CareFirst BlueCross BlueShield to Expand Access to PROPEL Steroid Releasing Implants to More Patients
athenahealth, Inc., a leading provider of network-enabled services and mobile applications for healthcare providers nationwide, today announced the acquisition of Filament Labs, Inc., d/b/a Patient IO, an Austin-based care coordination platform used by providers to engage patients and caregivers outside the four walls of the clinic.. Delivered as a simple and elegant mobile and web-based application, Patient IO turns care plans into actionable..."/>
Athenahealth Acquires Patient IO to Accelerate Patient-Centered Care
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement with SunGen Pharma, LLC to collaborate to develop and commercialize four generic pharmaceutical products.. Under the terms of the agreement, Elite and SunGen will share in the responsibilities and costs in the development of the products."/>
Elite Announces Development and License Agreement with SunGen Pharma LLC
Hemispherx Biopharma Inc., Vascular Biogenics Ltd, BioCryst Pharmaceuticals Inc., and Alnylam Pharmaceuticals Inc.."/>
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
Cryoport, Inc., the world's leading temperature-controlled logistics company serving the life sciences industry, today announced that it has initiated a novel and comprehensive logistics study to evaluate the impact of temperature and transport packaging at deep frozen temperatures on critical biomarkers and cell-therapy cancer vaccines, respectively, in conjunction with partners KCAS Bioanalytical and Biomarker Services and..."/>
Cryoport Partners with KCAS Bioanalytical and Biomarker Services and Heat Biologics on Comprehensive Logistics Study for Bioanalytical and Clinical Trial Materials
Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Conatus Pharmaceuticals Inc. to use the BreathID ® Methacetin Breath Test to monitor patients in a planned Phase IIb clinical trial evaluating emricasan. Emricasan is an investigational treatment for patients with chronic liver..."/>
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
Sagent Pharmaceuticals, Inc. at $21.75 per share, net to the holder in cash, without interest, less any applicable withholding taxes. The tender offer was effected by Nichi-Iko’ s wholly-owned subsidiary, Shepard Vision, Inc.. The depositary for the tender offer has advised Nichi-Iko and Sagent that, as of the expiration of the tender..."/>
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
Brookdale Senior Living Inc., Envision Healthcare Holdings Inc., Kindred Healthcare Inc., and Adeptus Health Inc.."/>
Healthcare Stocks on Investors' Radar -- Brookdale Senior Living, Envision Healthcare, Kindred Healthcare, and Adeptus Health
Rubicon Project Inc., Mitek Systems Inc., Innoviva Inc., and Proofpoint Inc.. These Application Software companies belong in the Technology sector, which was slightly lower at the closing bell on Friday, August 26, 2016."/>
Application Software Stocks Under Scanner -- Rubicon Project, Mitek Systems, Innoviva, and Proofpoint
ARIAD Pharmaceuticals, Inc. today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’ s business on Monday, September 12, 2016 at 2:50 p.m.. The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at..."/>
ARIAD to Present at the Morgan Stanley Global Healthcare Conference
Providence Service Corporation will maintain a significant interest and have representatives on Matrix’ s Board of Director Transaction values Matrix at $537.5 million Providence to receive gross cash proceeds of approximately $418 million before transaction costs, taxes, and customary post-closing adjustments STAMFORD, Conn., Aug. 29, 2016-- The Providence Service Corporation today..."/>
Providence Service Corporation and Frazier Healthcare Partners Announce Strategic Partnership in Matrix Medical Network
Celgene Corporation plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company’ s website at www.celgene.com. Wednesday, September 7, 2016, Celgene will present at the Citi 11th Annual Biotech Conference in Boston at 12 noon ET."/>
Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
Invacare Corporation on Friday declared a cash dividend of USD0.0125 per share on the company's common stock. In addition, the company announced that it will pay a cash dividend of USD.011364 per share on its Class B common stock. Both the dividends will be paid on 21 October 2016 to shareholders of record as of 13 October 2016.."/>
Invacare's board to pay quarterly dividend on common stock & Class B common stock
Abeona Therapeutics Inc.:. Low-dose cohort enrollment completed for ongoing study to evaluate ABO-102, first-in-man AAV gene therapy by single intravenous injection in patients with MPS IIIA, a rare lysosomal storage disease Encouraging safety profile and early biopotency observed in initial subjects. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for..."/>
Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients
Inovio Pharmaceuticals, Inc. today announced it has initiated a clinical study of its preventive Zika vaccine in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’ s placebo control design to provide exploratory signals of vaccine efficacy.. J. Joseph Kim, Inovio’ s..."/>
Inovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy
Ekso Bionics Holdings, Inc., a robotic exoskeleton company, today announced the company plans to participate in the 5 th Annual Gateway Conference hosted by the Liolios Group in San Francisco, CA.. Ekso Bionics’ management is scheduled to present Thursday, September 8 th at 9:30AM PT. Interested parties can access the live webcast on the investors section of the company’ s website at www.eksobionics.com."/>
Ekso Bionics to Present at the 2016 Gateway Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology652 Articles
Consumer Discretionary585 Articles
Financials437 Articles
Health Care379 Articles
Industrials371 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.